Cargando…
Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients
BACKGROUND: RAS assessment is mandatory for therapy decision in metastatic colorectal cancer (mCRC) patients. This determination is based on tumor tissue, however, genotyping of circulating tumor (ct)DNA offers clear advantages as a minimally invasive method that represents tumor heterogeneity. Our...
Autores principales: | Vidal, J, Muinelo, L, Dalmases, A, Jones, F, Edelstein, D, Iglesias, M, Orrillo, M, Abalo, A, Rodríguez, C, Brozos, E, Vidal, Y, Candamio, S, Vázquez, F, Ruiz, J, Guix, M, Visa, L, Sikri, V, Albanell, J, Bellosillo, B, López, R, Montagut, C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834035/ https://www.ncbi.nlm.nih.gov/pubmed/28419195 http://dx.doi.org/10.1093/annonc/mdx125 |
Ejemplares similares
-
Clinicopathological Profiles Associated with Discordant RAS Mutational Status between Liquid and Tissue Biopsies in a Real-World Cohort of Metastatic Colorectal Cancer
por: Brozos-Vázquez, Elena, et al.
Publicado: (2023) -
Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients
por: Montagut, C, et al.
Publicado: (2010) -
ctDNA to Guide Adjuvant Therapy in Localized Colorectal Cancer (CRC)
por: Masfarré, Laura, et al.
Publicado: (2021) -
Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report
por: Casadevall, David, et al.
Publicado: (2016) -
Predicting Outcome and Therapy Response in mCRC Patients Using an Indirect Method for CTCs Detection by a Multigene Expression Panel: A Multicentric Prospective Validation Study
por: Vidal Insua, Yolanda, et al.
Publicado: (2017)